Tirzepatide to be evaluated in a 52-week randomized trial for weight management in post-bariatric surgery patients with suboptimal loss.

Many individuals undergoing bariatric surgery, such as sleeve gastrectomy, experience suboptimal weight loss or significant weight regain over time, diminishing the long-term benefits of the procedure. This presents a critical unmet clinical need, as current interventions for post-bariatric weight regain are limited. GLP-1 and GIP receptor agonists, like tirzepatide, have demonstrated substantial efficacy in primary obesity and type 2 diabetes, leading to significant weight reduction and metabolic improvements. This trial aims to investigate whether this dual agonism can extend its benefits to a population where initial surgical intervention has not yielded sustained optimal results, addressing a key gap in long-term weight management strategies.

This is a randomized, double-blind, placebo-controlled clinical trial (NCT06734273) enrolling adult patients who underwent bariatric surgery at least one year prior and still present with obesity and insufficient weight loss. Participants will be randomly assigned to receive either tirzepatide or a placebo. The study intervention involves once-weekly subcutaneous injections for 52 weeks, starting at a low dose that is gradually increased according to a predefined titration schedule. Primary endpoint is total body weight loss. Secondary endpoints include changes in waist circumference, blood pressure, various blood tests related to metabolism and inflammation, and quality of life questionnaires.

This randomized, double-blind, placebo-controlled clinical trial (NCT06734273) is currently recruiting participants and is projected to complete in March 2028. Therefore, no findings are available at this time. The primary objective is to determine if tirzepatide leads to significantly greater weight loss compared to placebo after 52 weeks of treatment. Researchers will also assess secondary endpoints including changes in waist circumference, blood pressure, and various blood tests related to metabolism and inflammation. These include markers such as HbA1c, fasting glucose, lipid profiles, and inflammatory cytokines. Participants' quality of life will also be evaluated through questionnaires. The study aims to provide robust evidence on the efficacy of tirzepatide as an adjunctive therapy for individuals struggling with suboptimal weight loss or regain post-bariatric surgery. > The core finding, once available, will be the mean percentage total body weight loss (%TBWL) difference between the tirzepatide and placebo groups at 52 weeks. The absence of current results underscores the ongoing nature of this important investigation into a critical unmet need.

Written by TitrateLab, separately from the study summarized above.